TVGN Earnings — Tevogen Bio Holdings Inc. Common Stock Post-ER Performance | BigEarnings
TVGN — Tevogen Bio Holdings Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$7.91
Market Cap$33.1M
P/E—
52W Range$4.14 – $75.50
Next Earnings2026-08-13
About Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.